Yahoo Finance Growth Investors: Industry Analysts Just Upgraded Their Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Revenue Forecasts By 76%
Celebrations may be in order for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have sharply increased their revenue numbers, with a view that Arcturus Therapeutics Holdings will make substantially more sales than they'd previously expected.
Following the latest upgrade, the current consensus, from the eight analysts covering Arcturus Therapeutics Holdings, is for revenues of US$153m in 2023, which would reflect a painful 46% reduction in Arcturus Therapeutics Holdings' sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$87m in 2023. The consensus has definitely become more optimistic, showing a considerable lift to revenue forecasts.
See our latest analysis for Arcturus Therapeutics Holdings
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that sales are expected to reverse, with a forecast 56% annualised revenue decline to the end of 2023. That is a notable change from historical growth of 63% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 20% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Arcturus Therapeutics Holdings is expected to lag the wider industry.
The Bottom Line
The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. They also expect company revenue to perform worse than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Arcturus Therapeutics Holdings.
Hungry for more information? At least one of Arcturus Therapeutics Holdings' eight analysts has provided estimates out to 2025, which can be seen for free on our platform here.
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
